Iannone Robert's most recent trade in Jazz Pharmaceuticals plc was a trade of 6,209 Ordinary Shares done at an average price of $188.7 . Disclosure was reported to the exchange on March 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharma PLC | Robert Iannone | EVP, Global Head of R&D & CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 188.69 per share. | 05 Mar 2026 | 6,209 | 88,871 (0%) | 0% | 188.7 | 1,171,576 | Ordinary Shares |
| Jazz Pharma PLC | Robert Iannone | EVP, Global Head of R&D & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 14,822 | 95,080 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Robert Iannone | EVP, Global Head of R&D & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2026 | 11,699 | 84,398 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Robert Iannone | EVP, Global Head of R&D & CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 171.16 per share. | 16 Jan 2026 | 4,140 | 80,258 (0%) | 0% | 171.2 | 708,602 | Ordinary Shares |
| Jazz Pharma PLC | Robert Iannone | EVP, Global Head of R&D & CMO | Sale of securities on an exchange or to another person at price $ 168.26 per share. | 17 Nov 2025 | 7,159 | 72,628 (0%) | 0% | 168.3 | 1,204,573 | Ordinary Shares |
| Jazz Pharma PLC | Robert Iannone | EVP, Global Head of R&D & CMO | Sale of securities on an exchange or to another person at price $ 138.41 per share. | 10 Mar 2025 | 2,403 | 79,621 (0%) | 0% | 138.4 | 332,605 | Ordinary Shares |
| Jazz Pharma PLC | Robert Iannone | EVP, Global Head of R&D & CMO | Sale of securities on an exchange or to another person at price $ 138.21 per share. | 05 Mar 2025 | 5,532 | 83,572 (0%) | 0% | 138.2 | 764,578 | Ordinary Shares |
| Jazz Pharma PLC | Robert Iannone | EVP, Global Head of R&D & CMO | Sale or transfer of securities back to the company at price $ 138.95 per share. | 05 Mar 2025 | 5,239 | 89,104 (0%) | 0% | 138.9 | 727,959 | Ordinary Shares |
| Jazz Pharma PLC | Robert Iannone | EVP, Global Head of R&D & CMO | Sale of securities on an exchange or to another person at price $ 140.00 per share. | 05 Mar 2025 | 1,548 | 82,024 (0%) | 0% | 140 | 216,720 | Ordinary Shares |
| Jazz Pharma PLC | Robert Iannone | EVP, G R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 17,718 | 85,484 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Robert Iannone | EVP, G R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 8,859 | 94,343 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Robert Iannone | EVP, G R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 7,506 | 69,947 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Robert Iannone | EVP, G R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 122.62 per share. | 17 Jan 2025 | 2,181 | 67,766 (0%) | 0% | 122.6 | 267,434 | Ordinary Shares |
| ITeos Therapeutics Inc | Robert Iannone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 24,200 | 24,200 | - | - | Stock Option (Right to Buy) | |
| Jazz Pharma PLC | Robert Iannone | EVP, Global Head of R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.53 per share. | 05 Mar 2024 | 4,294 | 62,226 (0%) | 0% | 117.5 | 504,674 | Ordinary Shares |
| Jazz Pharma PLC | Robert Iannone | EVP, Global Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 16,928 | 66,520 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Iannone Robert | EVP, Global Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2024 | 5,970 | 51,322 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Iannone Robert | EVP, Global Head of R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 119.13 per share. | 17 Jan 2024 | 1,730 | 49,592 (0%) | 0% | 119.1 | 206,095 | Ordinary Shares |
| ITeos Therapeutics Inc | Robert Iannone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 22,383 | 22,383 | - | - | Stock Option (Right to Buy) | |
| Jazz Pharma PLC | Robert Iannone | EVP, Global Head of Research a | Sale or transfer of securities back to the company at price $ 129.73 per share. | 05 Jun 2023 | 1,311 | 45,315 (0%) | 0% | 129.7 | 170,076 | Ordinary Shares |
| Jazz Pharma PLC | Robert Iannone | EVP, Global Head of Research a | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 12,447 | 48,763 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Robert Iannone | EVP, Global Head of Research a | Payment of exercise price or tax liability using portion of securities received from the company at price $ 142.78 per share. | 03 Mar 2023 | 2,274 | 46,489 (0%) | 0% | 142.8 | 324,682 | Ordinary Shares |
| Jazz Pharma PLC | Robert Iannone | EVP, Global Head of R&D | Sale of securities on an exchange or to another person at price $ 151.54 per share. | 09 Dec 2022 | 1,844 | 36,316 (0%) | 0% | 151.5 | 279,440 | Ordinary Shares |
| Jazz Pharma PLC | Robert Iannone | EVP, Global Head of R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 149.25 per share. | 06 Jun 2022 | 1,295 | 38,109 (0%) | 0% | 149.3 | 193,279 | Ordinary Shares |
| Jazz Pharma PLC | Robert Iannone | EVP, Global Head of R&D and Ch | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 11,374 | 40,584 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Robert Iannone | EVP, Global Head of R&D and Ch | Payment of exercise price or tax liability using portion of securities received from the company at price $ 153.96 per share. | 03 Mar 2022 | 1,327 | 39,257 (0%) | 0% | 154.0 | 204,305 | Ordinary Shares |
| ITeos Therapeutics Inc | Robert Iannone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 4,560 | 4,560 | - | - | Stock Option (Right to Buy) | |
| Jazz Pharma PLC | Robert Iannone | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 176.47 per share. | 05 Jun 2021 | 1,206 | 29,086 (0%) | 0% | 176.5 | 212,823 | Ordinary Shares |
| ITeos Therapeutics Inc | Robert Iannone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2021 | 33,217 | 0 | - | - | Stock Option (Right to Buy) |